直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Strict Limits on Claim Amendments During IPR

October 03, 2013

Authored and Edited by Arpita Bhattacharyya, Ph.D.; Jeffrey C. Totten

The patent statute permits a patent owner to file one motion to amend its claims after an IPR is instituted. In practice, however, the process is not so simple. At the recent IPO Annual Meeting in Boston, Lead Administrative Patent Judge, Hon. Michael Tierney, pointed to a decision in Idle Free Sys. Inc. v. Bergstrom. Inc. as an example of the Board’s approach to claim-amendment practice.

Under 37 C.F.R. § 42.121(a), a patent owner must confer with the Board before filing a motion to amend. Although the decision accepts that “it was not unreasonable for Bergstrom to have considered the initial conference call as satisfying the conferring requirement,” it nevertheless dismissed the patent owner’s motion to amend for failing to confer with the Board “about the specific amendments contemplated.”

The Board then provided extensive guidance for a proper motion to amend. The Board noted that § 42.121(a)(3) provides for a “reasonable number” of substitute claims, but with the express presumption that “only one substitute claim would be needed to replace each challenged claim.” Thus, "in the absence of special circumstance, a challenged claim can be replaced by only one claim.” Without clarifying what would constitute a “special circumstance,” the Board explained that “a desire to obtain a new set of claims having a hierarchy of different scope” would not suffice. The patent owner should also identify on a claim-by-claim basis the “contingency of substitution, e.g., which [substitute] claim for which [challenged] claim and in what circumstance.”

The Board also emphasized that IPR was not a permissible forum for broadening claim scope or remodeling claim structure according to a different strategy. 37 C.F.R. § 42.121(2)(i) only permits amendments responsive to grounds of unpatentability raised at trial, and a proposed substitute claim would not be responsive to an alleged ground of unpatentability if it “does not either include or narrow each feature of the challenged claim being replaced.” Moreover, because the patent owner bears the burden of demonstrating patentability of the proposed claims under 37 C.F.R. § 42.20(c), the patent owner should identify the feature(s) added to each substitute claim and explain how the proposed claims are patentable over both the prior art of record and any additional prior art known to the patent owner.

Thus, Idle Free highlights the limitations for amending claims during an IPR. As the Board suggested, patent owners may consider ex parte reexamination or reissue, perhaps concurrently with the IPR, to pursue claim amendments not permissible during IPR. 

Tags

claim amendments, motions to amend (MTA), substitute claims

Contacts

Jeffrey C. Totten
Partner
Washington, DC
+1 202 408 4232
Email

Copyright © 2013 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Conference

4th Global Patent Litigation FORUM

October 29, 2026

Munich

Lecture

Resolving Patent Suits Without Settlement Payments

September 3, 2026

Virtual

Conference

2026 China Pharmaceutical Innovation Conference

July 22-24, 2026

Shanghai

Webinar

Early Motions in Trade Secret Litigation – Offensive and Defensive Insights

July 15, 2026

Webinar

Federal Circuit IP Blog

“2” Does Not Provide Written Description Support for “1”: Federal Circuit Affirms District Court’s Invalidation of Patent

July 8, 2026

Federal Circuit IP Blog

Federal Circuit Vacates and Remands Infringement and Damages Judgment After Erroneous Verdict Form and Eligibility Analysis

July 8, 2026

At the PTAB Blog

Federal Circuit PTAB Appeal Statistics for March–May 2026

July 2, 2026

Articles

EPR Academy, Part 4 of 6: Choosing Between EPR, IPR, PGR, and Reissue

July 1, 2026

At the PTAB Blog

Deadline Evolution: Director Extends Deadline for Requesting Director Review of Institution Grants to 30 Days

June 30, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP